Apimeds Pharmaceuticals US Inc
APUS1.540USD
-0.230-12.99%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
19.37MMarket Cap
LossP/E TTM
More Details of Apimeds Pharmaceuticals US Inc Company
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Apimeds Pharmaceuticals US Inc Info
Ticker SymbolAPUS
Company nameApimeds Pharmaceuticals US Inc
IPO dateMay 09, 2025
CEOMenon (Vin)
Number of employees2
Security typeOrdinary Share
Fiscal year-endMay 09
Address100 Matawan Road
CityMATAWAN
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code07747
Phone18482015010
Websitehttps://www.apimedsus.com/
Ticker SymbolAPUS
IPO dateMay 09, 2025
CEOMenon (Vin)
Company Executives of Apimeds Pharmaceuticals US Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erik C. Emerson
Mr. Erik C. Emerson
President, Director
President, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
Mr. Erick Frim
Mr. Erick Frim
Chief Financial Officer
Chief Financial Officer
--
--
Vin Menon
Vin Menon
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Erik C. Emerson
Mr. Erik C. Emerson
President, Director
President, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
Mr. Erick Frim
Mr. Erick Frim
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Apimeds, Inc.
34.89%
Inscobee, Inc.
16.13%
Dominus IB, Inc
6.36%
Emerson (Erik C)
5.96%
Koo (Jakap)
5.12%
Other
31.53%
Shareholders
Shareholders
Proportion
Apimeds, Inc.
34.89%
Inscobee, Inc.
16.13%
Dominus IB, Inc
6.36%
Emerson (Erik C)
5.96%
Koo (Jakap)
5.12%
Other
31.53%
Shareholder Types
Shareholders
Proportion
Corporation
62.15%
Individual Investor
13.29%
Bank and Trust
1.99%
Investment Advisor
0.58%
Investment Advisor/Hedge Fund
0.24%
Hedge Fund
0.22%
Venture Capital
0.15%
Other
21.38%
Institutional Shareholding
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
7
117.07K
0.93%
+97.92K
2025Q2
7
9.49M
81.96%
+7.39M
2025Q1
2
2.10M
18.15%
+2.10M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Apimeds, Inc.
4.39M
34.89%
+4.39M
--
May 12, 2025
Inscobee, Inc.
2.03M
16.13%
+544.04K
+36.65%
May 12, 2025
Dominus IB, Inc
800.00K
6.36%
+800.00K
--
May 09, 2025
Emerson (Erik C)
750.00K
5.96%
+750.00K
--
May 16, 2025
Koo (Jakap)
643.88K
5.12%
+28.50K
+4.63%
May 12, 2025
Seed 1 ho
600.00K
4.77%
+600.00K
--
May 09, 2025
Kim (Christopher)
277.50K
2.21%
+277.50K
--
May 16, 2025
The Vanguard Group, Inc.
7.17K
0.06%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
11.97K
0.1%
+9.73K
+434.33%
Aug 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Apimeds Pharmaceuticals US Inc?
The top five shareholders of Apimeds Pharmaceuticals US Inc are:
Apimeds, Inc. holds 4.39M shares, accounting for 34.89% of the total shares.
Inscobee, Inc. holds 2.03M shares, accounting for 16.13% of the total shares.
Dominus IB, Inc holds 800.00K shares, accounting for 6.36% of the total shares.
Emerson (Erik C) holds 750.00K shares, accounting for 5.96% of the total shares.
Koo (Jakap) holds 643.88K shares, accounting for 5.12% of the total shares.
Apimeds, Inc. holds 4.39M shares, accounting for 34.89% of the total shares.
Inscobee, Inc. holds 2.03M shares, accounting for 16.13% of the total shares.
Dominus IB, Inc holds 800.00K shares, accounting for 6.36% of the total shares.
Emerson (Erik C) holds 750.00K shares, accounting for 5.96% of the total shares.
Koo (Jakap) holds 643.88K shares, accounting for 5.12% of the total shares.
What are the top three shareholder types of Apimeds Pharmaceuticals US Inc?
The top three shareholder types of Apimeds Pharmaceuticals US Inc are:
Apimeds, Inc.
Inscobee, Inc.
Dominus IB, Inc
Apimeds, Inc.
Inscobee, Inc.
Dominus IB, Inc
How many institutions hold shares of Apimeds Pharmaceuticals US Inc (APUS)?
As of 2025Q3, 7 institutions hold shares of Apimeds Pharmaceuticals US Inc, with a combined market value of approximately 117.07K, accounting for 0.93% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -81.03%.
What is the biggest source of revenue for Apimeds Pharmaceuticals US Inc?
In --, the -- business generated the highest revenue for Apimeds Pharmaceuticals US Inc, amounting to -- and accounting for --% of total revenue.
